Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center).
Efficient modes of extracorporeal blood purification are available today for apheresis treatment of progressive atherosclerosis, autoimmune disease, or for improving hemorheology. Advanced technology and sophisticated care render apheresis treatment selective, safe and tolerable. Our task is to constantly update indications for apheresis based on best evidence available and good clinical practice, as well as, to determine how apheresis therapy can be made available to those in need or with otherwise refractory disease. Presenting examples of lipid apheresis, rheopheresis, or immunoadsorption for treatment of hypercholesterolemia, hyperlipoproteinemia (a), acute hearing loss, refractory or exacerbating multiple sclerosis, we highlight real world obstacles for implementation of treatment, resulting in still too many patients with proven or recommended indication left untreated. Based on the experience of the largest apheresis center in Germany, with more than 3,300 treatments per year, we depict the necessary structure for identification of patients, defining indication, referral, implementation of therapy, and reimbursement. Apheresis is unfamiliar to most patients and many practitioners or consultants. Nephrologists, performing >90% of apheresis treatments in Germany, have to form a network for referral comprising all regional care-givers, general practitioners as well as the respective specialists (mainly, cardiologists, endocrinologists, diabetologists, ORL specialists, neurologists, ophthalmologists, or rheumatologists), and insurances or other cost-bearing parties for offering a scientifically approved therapeutic regimen and comprehensive care. We have realized this concept in a high volume apheresis center acting in a closely knit network characterized by an unrelenting effort at ongoing medical education. As a consequence, we include approximately 10 times more patients with appropriate diagnoses in our apheresis program as compared to the national average.
Dres. Heigl, Hettich & Partner, Medizinisches Versorgungszentrum Kempten-Allgäu, Robert-Weixler-Strabetae 9, 87439 Kempten, Germany. heigl@mvz-kempten.de
Franz
F
Heigl
Reinhard
R
Hettich
Norbert
N
Lotz
Harduin
H
Reeg
Bernadette
B
Eder
Karin
K
Steckholzer-Kroth
Michael
M
Browatzki
Kerstin
K
Harre
Rainer
R
Arendt
D000906:Antibodies / Q000009:adverse effects*; D001781:Blood Component Removal / Q000009:adverse effects / Q000379:methods*; D019033:Delivery of Health Care, Integrated; D005858:Germany; D006297:Health Services Accessibility; D034381:Hearing Loss / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D018056:Hemorheology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D007163:Immunosorbent Techniques / Q000009:adverse effects; D008055:Lipids / Q000097:blood*; D009103:Multiple Sclerosis / Q000097:blood / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D010348:Patient Care Team; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
D000906:Antibodies; D008055:Lipids